Home > Publications database > Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances. > print

001     276067
005     20240229154955.0
024 7 _ |a 10.3390/ijms24097922
|2 doi
024 7 _ |a pmid:37175627
|2 pmid
024 7 _ |a pmc:PMC10178331
|2 pmc
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
024 7 _ |a altmetric:146704941
|2 altmetric
037 _ _ |a DKFZ-2023-00973
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Kasi, Phanindra Babu
|b 0
245 _ _ |a Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.
260 _ _ |a Basel
|c 2023
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1692021359_20939
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C020#
520 _ _ |a Colorectal cancer (CRC) is the third most common cancer worldwide, and metastatic CRC is a fatal disease. The CRC-affected tissues show several molecular markers that could be used as a fresh strategy to create newer methods of treating the condition. The liver and the peritoneum are where metastasis occurs most frequently. Once the tumor has metastasized to the liver, peritoneal carcinomatosis is frequently regarded as the disease's final stage. However, nearly 50% of CRC patients with peritoneal carcinomatosis do not have liver metastases. New diagnostic and therapeutic approaches must be developed due to the disease's poor response to present treatment choices in advanced stages and the necessity of an accurate diagnosis in the early stages. Many unique and amazing nanomaterials with promise for both diagnosis and treatment may be found in nanotechnology. Numerous nanomaterials and nanoformulations, including carbon nanotubes, dendrimers, liposomes, silica nanoparticles, gold nanoparticles, metal-organic frameworks, core-shell polymeric nano-formulations, and nano-emulsion systems, among others, can be used for targeted anticancer drug delivery and diagnostic purposes in CRC. Theranostic approaches combined with nanomedicine have been proposed as a revolutionary approach to improve CRC detection and treatment. This review highlights recent studies, potential, and challenges for the development of nanoplatforms for the detection and treatment of CRC.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a cancer therapy
|2 Other
650 _ 7 |a clinical status
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a nanomedicine
|2 Other
650 _ 7 |a theranostics
|2 Other
650 _ 7 |a Nanotubes, Carbon
|2 NLM Chemicals
650 _ 7 |a Gold
|0 7440-57-5
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Nanomedicine: methods
|2 MeSH
650 _ 2 |a Peritoneal Neoplasms
|2 MeSH
650 _ 2 |a Precision Medicine
|2 MeSH
650 _ 2 |a Nanotubes, Carbon
|2 MeSH
650 _ 2 |a Gold
|2 MeSH
650 _ 2 |a Metal Nanoparticles
|2 MeSH
650 _ 2 |a Nanoparticles: therapeutic use
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Theranostic Nanomedicine
|2 MeSH
650 _ 2 |a Drug Delivery Systems: methods
|2 MeSH
700 1 _ |a Mallela, Venkata Ramana
|0 0000-0001-9664-481X
|b 1
700 1 _ |a Ambrozkiewicz, Filip
|0 0000-0001-6850-780X
|b 2
700 1 _ |a Trailin, Andriy
|0 0000-0001-8888-0759
|b 3
700 1 _ |a Liška, Václav
|b 4
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.3390/ijms24097922
|g Vol. 24, no. 9, p. 7922 -
|0 PERI:(DE-600)2019364-6
|n 9
|p 7922
|t International journal of molecular sciences
|v 24
|y 2023
|x 1422-0067
909 C O |p VDB
|o oai:inrepo02.dkfz.de:276067
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-09-04T08:27:04Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J MOL SCI : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-07T16:31:47Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-07T16:31:47Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-07T16:31:47Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J MOL SCI : 2022
|d 2023-08-25
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21